Temelimab

Temelimab (also known as GNbAC1[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2][3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.[1] The drug is also being studied for cognitive impairment in long COVID.[4]

References

  1. 1 2 Irfan, Shayan Ali; Murtaza, Minha; Ahmed, Ali; Altaf, Hina; Ali, Abid Anwar; Shabbir, Naqiha; Baig, Mirza Mehmood Ali (2022). "Promising role of temelimab in multiple sclerosis treatment". Multiple Sclerosis and Related Disorders. 61: 103743. doi:10.1016/j.msard.2022.103743. ISSN 2211-0348.
  2. ↑ Mouliou, Dimitra S.; Dardiotis, Efthimios (2022). "Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?". Multiple Sclerosis and Related Disorders. 64: 103938. doi:10.1016/j.msard.2022.103938. PMC 9169463. PMID 35717898.
  3. ↑ Kornmann, Gabrielle; Curtin, François (2020). "Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review". Drug Safety. 43 (12): 1287–1296. doi:10.1007/s40264-020-00988-3. ISSN 0114-5916.
  4. ↑ Bonilla, Hector; Peluso, Michael J.; Rodgers, Kathleen; Aberg, Judith A.; Patterson, Thomas F.; Tamburro, Robert; Baizer, Lawrence; Goldman, Jason D.; Rouphael, Nadine; Deitchman, Amelia; Fine, Jeffrey; Fontelo, Paul; Kim, Arthur Y.; Shaw, Gwendolyn; Stratford, Jeran (2023-03-09). "Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative". Frontiers in Immunology. 14. doi:10.3389/fimmu.2023.1129459. ISSN 1664-3224. PMC 10034329. PMID 36969241.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.